Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National Taiwan University Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Seoul National University Bundang Hospital, National Cheng Kung University Hospital, National Cheng Kung University, Olivia Newton-John Cancer Research Institute, Chris O’Brien Lifehouse, Cedars-Sinai Medical Center, University of California, Los Angeles, AstraZeneca (United Kingdom), AstraZeneca (United States), Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2666096222